Apopharma

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Deferiprone
Drug: Placebo

First Posted Date: 2013-11-21

Last Posted Date: 2014-12-23

Lead Sponsor: ApoPharma

Target Recruit Count: 64

Registration Number: NCT01989455

Locations: 🇨🇦
Algorithme Pharma Inc., Mont-Royal, Quebec, Canada

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

Phase 4

Completed

Conditions: Prolonged QTc Interval

Interventions: Drug: Deferiprone
Drug: deferiprone matching placebo tablets
Drug: moxifloxacin
Drug: placebo

First Posted Date: 2013-05-23

Last Posted Date: 2014-11-12

Lead Sponsor: ApoPharma

Target Recruit Count: 50

Registration Number: NCT01860703

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Active Drug Surveillance Program of Ferriprox Use

Completed

Conditions: Transfusional Iron Overload

First Posted Date: 2013-04-24

Last Posted Date: 2013-04-24

Lead Sponsor: ApoPharma

Target Recruit Count: 294

Registration Number: NCT01838291

Locations: 🇪🇬
Zagazig University; Thalassemia Association, Zagazig, Egypt
🇨🇾
Thalassemia Center of North Cyprus Turkish Republic (KKTC), Nicosia, Cyprus
🇸🇦
Maternity and Children's Hospital, Maddinah, Saudi Arabia

and more 11 locations

Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: single 1500 mg dose of Ferriprox

First Posted Date: 2013-04-19

Last Posted Date: 2015-07-24

Lead Sponsor: ApoPharma

Target Recruit Count: 8

Registration Number: NCT01835496

Locations: 🇨🇦
CHUM-Hôpital Notre-Dame, Montreal, Quebec, Canada

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment

Phase 4

Completed

Conditions: Renal Impairment

Interventions: Drug: Deferiprone

First Posted Date: 2013-01-18

Last Posted Date: 2014-08-26

Lead Sponsor: ApoPharma

Target Recruit Count: 32

Registration Number: NCT01770652

Locations: 🇨🇦
Algorithme Pharma Inc., Mount-Royal, Quebec, Canada
🇨🇦
Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

Phase 4

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Ferriprox®

First Posted Date: 2013-01-14

Last Posted Date: 2014-09-10

Lead Sponsor: ApoPharma

Target Recruit Count: 21

Registration Number: NCT01767103

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

Phase 3

Completed

Conditions: Pantothenate Kinase-Associated Neurodegeneration

Interventions: Drug: Placebo
Drug: Deferiprone oral solution

First Posted Date: 2012-12-05

Last Posted Date: 2019-07-05

Lead Sponsor: ApoPharma

Target Recruit Count: 89

Registration Number: NCT01741532

Locations: 🇺🇸
Children's Hospital & Research Center at Oakland, Oakland, California, United States
🇬🇧
Newcastle University Institute of Human Genetics, Newcastle Upon Tyne, United Kingdom
🇮🇹
Foundation Neurological Institute C. Besta, Milan, Italy

and more 1 locations

Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Apo805K1

First Posted Date: 2011-12-02

Last Posted Date: 2015-02-20

Lead Sponsor: ApoPharma

Target Recruit Count: 60

Registration Number: NCT01483924

Locations: 🇺🇸
Center for Clinical Studies, Houston, Texas, United States
🇺🇸
Axis Clinical Trials, Los Angeles, California, United States
🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada

and more 2 locations

A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia

Phase 2

Completed

Conditions: Friedreich's Ataxia

Interventions: Drug: Deferiprone oral solution 100mg/mL
Drug: Deferiprone oral solution 100 mg/mL

First Posted Date: 2009-05-12

Last Posted Date: 2011-06-27

Lead Sponsor: ApoPharma

Target Recruit Count: 36

Registration Number: NCT00897221

Locations: 🇫🇷
Hospital Necker-Enfants Malades, Paris, France
🇧🇪
Hospital Erasme, Brussels, Belgium
🇮🇹
Fondazione IRCCS Istituto Neurologico "C. Besta", Milan, Italy

and more 1 locations

A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

Phase 1

Completed

Conditions: Friedreich's Ataxia

Interventions: Drug: placebo
Drug: deferiprone

First Posted Date: 2007-09-17

Last Posted Date: 2010-06-02

Lead Sponsor: ApoPharma

Target Recruit Count: 80

Registration Number: NCT00530127

Locations: 🇦🇺
Murdoch Children's Research Institute, Victoria, Australia
🇧🇪
Hospital Erasme, Brussels, Belgium
🇪🇸
La Fundacion Para la Investigacion Biomedica, Madrid, Spain

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy